# Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS

> **NCT04681118** · — · NO_LONGER_AVAILABLE · sponsor: **Brainstorm-Cell Therapeutics**

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **BIOLOGICAL:** NurOwn (MSC-NTF cells)

## Key facts

- **NCT ID:** NCT04681118
- **Lead sponsor:** Brainstorm-Cell Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04681118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04681118, "Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04681118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*